Advances in treating glioblastoma
Shiao-Pei Weathers and Mark R. Gilbert*

Address: Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 431, Houston, TX 77030, USA

* Corresponding author: Mark R. Gilbert (mrgilbert@mdanderson.org)

F1000Prime Reports 2014, 6:46 (doi:10.12703/P6-46)

All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/m/6/46

Abstract
Glioblastoma is the most common and most aggressive primary brain tumor in adults. Optimized standard treatment only confers a modest improvement in progression and overall survival, underscoring the pressing need for the development of novel therapies. Our understanding of glioblastoma (a molecularly heterogeneous disorder) has been accelerated in the setting of large scale genomic analyses, lending insight into potential actionable targets. Antiangiogenic therapies have been used in the treatment of glioblastoma, and our understanding of the means to optimize the role of these agents is continuing to evolve. Recently, immunotherapy has garnered increasing attention as a therapeutic approach in the treatment of gliomas. Promising novel approaches are under active development in the treatment of glioblastoma.

Introduction
Glioblastoma is the most common malignant primary brain tumor in adults and invariably carries a poor prognosis. Despite optimal multimodality treatment that typically includes surgery, radiation, and cytotoxic chemotherapy, recent clinical trials have reported a median survival of only 14–16 months with a 26–33% 2 year survival rate [1,2]. The challenges in developing effective treatments for patients with glioblastoma are attributed to the relative rarity of the tumor and its molecular heterogeneity. Varying susceptibility to treatment toxicities further complicates treatment planning. New therapeutic approaches are needed to improve the outcomes of patients with glioblastoma.

Current standard of care for glioblastoma
Glioblastomas are inherently aggressive tumors. Their infiltrative behavior renders them difficult to completely resect. Nevertheless, maximal safe surgical resection does improve prognosis and is therefore recommended as the initial step in the management of glioblastoma [3,4]. The addition of chemotherapy to radiation emerged as the standard of care for glioblastoma based on the seminal study performed by Stupp and colleagues [1].

Temozolomide, an alkylating cytotoxic agent, administered concurrently at a dose of 75 mg/m² daily during the course of regional radiotherapy, followed by maintenance temozolomide given at a dose of 150–200 mg/m² days 1–5 every 28 days for maintenance, resulted in an improvement in median overall survival from 12.1 to 14.6 months when compared to patients treated with radiation alone. The 2 year survival rate was 26.5% in patients who received chemotherapy in addition to radiotherapy compared to 10.4% in those patients who received radiotherapy alone. The addition of temozolomide to radiotherapy had clearly demonstrated a statistically significant survival benefit.

O-6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that reverses the damage induced by alkylating agents (such as temozolomide) and has been implicated as a major mechanism of resistance to alkylating agents [5]. Methylation of the gene promoter results in decreased expression of the enzyme, rendering tumor cells more susceptible to alkylating agents, which has been observed to translate into a striking survival benefit for those patients treated with radiotherapy and temozolomide [6]. Dose dense scheduling of
temozolomide results in prolonged depletion of MGMT, suggesting that prolonged exposure to temozolomide may result in improved survival in patients with newly diagnosed glioblastoma. This hypothesis was studied in a randomized phase III clinical trial comparing standard adjuvant temozolomide (days 1–5 every 28 days) with a dose dense schedule (days 1–21 every 28 days). No statistically significant difference in either median overall survival or median progression free survival was observed between the dose dense and standard treatment arms of the study. Although dose dense temozolomide was not found to confer a survival benefit for newly diagnosed glioblastoma, the study did reaffirm the prognostic significance of MGMT methylation as evidenced by the improved overall survival, progression free survival, and response in the methylated versus the unmethylated patients [2].

**Molecular heterogeneity**

There is a growing body of evidence that our lack of effective therapies is related to our increasing recognition that glioblastoma is a molecularly heterogeneous disorder. This heterogeneity is both intertumoral and intratumoral, further complicated by continued molecular changes over time; this is clearly a major challenge in developing effective treatments. Large scale profiling efforts have accelerated our understanding of this complex disease. The Cancer Genome Atlas (TCGA) has attempted to catalog the spectrum of molecular abnormalities seen in glioblastoma, spurring the development of molecular subtypes. The analysis specifically designated four subtypes termed proneural, neural, classical, and mesenchymal, distinguished from each other based on shared genomic, epigenomic, and transcriptional features [7]. More recently, a similar classification schema was developed using tumor methylation arrays along with other molecular testing, and now has defined six sub-classifications if pediatric glioblastoma is included [8]. Figure 1 highlights these key genetic and epigenetic findings in six glioblastoma subgroups. Although the prognostic and predictive significance of these tumor subclasses remains unclear and currently has a limited role in treatment decisions, the recognition of molecular subclases has piqued interest that tumor profiling may translate into the development of targeted therapy.

**Targeted therapy**

The efficacy of molecularly based targeted therapy has been validated in the treatment of other cancers. Chronic myeloid leukemia (CML), a myeloproliferative disorder, has a characteristic abnormality, the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of chromosomes 9 and 22. This translocation results in the generation of the fusion protein BCR-ABL, which is a constitutively activated tyrosine kinase in CML. Mutational analysis established that the tyrosine kinase activity of the protein was necessary for its oncogenic activity. This recognition of the essential role of BCR-ABL tyrosine kinase activity in CML was then exploited in the development of Imatinib which acts as an inhibitor of the BCR-ABL tyrosine kinase [9]. Imatinib revolutionized the treatment of Ph(+) CML and has emerged as a paradigm for the development of targeted therapy in cancer therapeutics.

Glioblastoma is now one of the most molecularly characterized of all human cancers. Molecular profiling efforts have resulted in the identification of molecular prognostic factors as well as identified molecular vulnerabilities that could be potentially targeted in the development of novel treatments in glioblastoma. Table 1 highlights some of the potential actionable targets in glioblastoma. One of the first abnormalities recognized in glioblastoma was alterations in the epidermal growth factor receptor (EGFR), which is seen in approximately 40–50% of patients. Amplification or overexpression of EGFR is most common, but a relatively high percent of tumors also demonstrate a unique mutation designated EGFRvIII. EGFRvIII mutation represents a partial deletion of the extracellular domain that constitutively activates the receptor of the ligand [10]. EGFR mutations are a compelling drug target in glioblastoma. The relatively high frequency of EGFR amplification, EGFRvIII mutation, and other EGFR extracellular domain mutations suggest that EGFR tyrosine kinase inhibitors would be an appropriate actionable target in glioblastoma. Unfortunately, anti-EGFR kinase therapy trials with erlotinib and gefitinib in glioblastoma have been largely unsuccessful, even in patients with tumors where the gene is overexpressed or the EGFRvIII mutation is present [11–14]. EGFR inhibitor resistance has led to an improved understanding of the mechanism mediating resistance. PTEN is an important factor in determining EGFR tyrosine kinase inhibitor response. EGFRvIII expression and loss of PTEN results in resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients and preclinical models, as signal flux through the phosphatidylinositol 3-kinase (PI3K) signaling pathway is maintained [15]. Recent studies examining potential EGFR pathway inhibition suggest that agents that target the intracellular component, such as lapatinib, may have greater efficacy [16].

PI3K pathway-activating genetic lesions occur in almost 90% of glioblastomas arising due to amplification and/or mutation in EGFR or other receptor tyrosine kinases (RTKs), PI3KCA, or PTEN loss. Protein kinase B (AKT)
phosphorylation is commonly observed [17]. Recognition that PI3K/AKT signaling is hyperactivated has made PI3K, and its key downstream effector AKT, appealing targets for therapy in glioblastoma. PI3K and AKT inhibitors are currently in early phase clinical trials. Although the PI3K pathway remains an intriguing therapeutic target, early studies were complicated by unacceptable toxicities, likely related to the importance of these pathways in normal

---

**Figure 1. Graphical summary of key molecular and biologic characteristics of glioblastoma subgroups**

<table>
<thead>
<tr>
<th>Mutations / Cytogenetics</th>
<th>DNA Methylation</th>
<th>Gene Expression</th>
<th>IHC Protein Marker</th>
<th>Age Distribution (years)</th>
<th>Tumor Location</th>
<th>Patient Survival (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IDH</td>
<td>K27</td>
<td>G34</td>
<td>RTK I</td>
<td>MESENCHYMAL</td>
<td>RTK II</td>
<td></td>
</tr>
<tr>
<td>IDH&lt;sup&gt;m&lt;/sup&gt;</td>
<td>H3F3A&lt;sup&gt;m&lt;/sup&gt;K27</td>
<td>H3F3A&lt;sup&gt;m&lt;/sup&gt;G34</td>
<td>PDGFRA amp&lt;sup&gt;l&lt;/sup&gt;</td>
<td>EGFR amp&lt;sup&gt;l&lt;/sup&gt;</td>
<td>CDKN2A del</td>
<td></td>
</tr>
<tr>
<td>TP53&lt;sup&gt;mt&lt;/sup&gt;</td>
<td>TP53&lt;sup&gt;mt&lt;/sup&gt;</td>
<td>TP53&lt;sup&gt;mt&lt;/sup&gt;</td>
<td>CDKN2A del.</td>
<td>CNV&lt;sup&gt;low&lt;/sup&gt;</td>
<td>CDKN2A del</td>
<td></td>
</tr>
<tr>
<td>CIMP+</td>
<td>CHOP+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proneural</td>
<td>Proneural</td>
<td>Mixed</td>
<td>Proneural</td>
<td>Mesenchymal</td>
<td>Classical</td>
<td></td>
</tr>
<tr>
<td>IDH&lt;sup&gt;R132H&lt;/sup&gt;</td>
<td>OLig2&lt;sup&gt;+&lt;/sup&gt;/FOXG1</td>
<td>OLig2&lt;sup&gt;+&lt;/sup&gt;/FOXG1</td>
<td>OLig2&lt;sup&gt;+&lt;/sup&gt;/FOXG1</td>
<td>OLig2&lt;sup&gt;+&lt;/sup&gt;/FOXG1</td>
<td>OLig2&lt;sup&gt;+&lt;/sup&gt;/FOXG1</td>
<td>OLig2&lt;sup&gt;+&lt;/sup&gt;/FOXG1</td>
</tr>
<tr>
<td>Age 0-60-90</td>
<td>Age 0-60-90</td>
<td>Age 0-60-90</td>
<td>Age 0-60-90</td>
<td>Age 0-60-90</td>
<td>Age 0-60-90</td>
<td>Age 0-60-90</td>
</tr>
<tr>
<td>Brain location</td>
<td>Brain location</td>
<td>Brain location</td>
<td>Brain location</td>
<td>Brain location</td>
<td>Brain location</td>
<td>Brain location</td>
</tr>
<tr>
<td>Survival 0-60-120</td>
<td>Survival 0-60-120</td>
<td>Survival 0-60-120</td>
<td>Survival 0-60-120</td>
<td>Survival 0-60-120</td>
<td>Survival 0-60-120</td>
<td>Survival 0-60-120</td>
</tr>
</tbody>
</table>


Abbreviations: CHOP, CpG hypomethylator phenotype; CIMP, CpG island methylator phenotype; EGFR, epidermal growth factor receptor; IDH, isocitrate dehydrogenase; PDGFRA, platelet derived growth factor receptor; RTK, receptor tyrosine kinase.
cellular homeostasis. More selective inhibitors are currently in early phase clinical trials for glioblastoma.

Identification of an actionable gene mutation or alteration in glioblastoma is exemplified in the work done by Singh and colleagues [18]. A small subset of glioblastomas harbor an oncogenic chromosomal translocation that fuse in-frame the tyrosine kinase coding domains of fibroblast growth factor receptor (FGFR) genes (FGFR1 or FGFR3) to the transforming acidic coiled-coil (TACC) coding domains of TACC1 or TACC3, respectively. This FGFR-TACC fusion protein was found to display oncogenic activity in the mouse brain. Oral administration of an FGFR inhibitor was found to prolong the survival of mice harboring the intracranial FGFR3-TACC3 initiated glioma, suggesting that targeted FGFR kinase inhibition may benefit the small subset of glioblastoma patients with FGFR3-TACC2 fusions [18]. Clinical trials specifically targeting this unique fusion protein are in development for glioblastoma. However, the very low incidence of the mutation (approximately 3%) will render accrual of patients for the clinical trial challenging.

Isocitrate dehydrogenase (IDH) mutations in gliomas are now known to be a positive prognostic factor, with an increase in overall survival noted in patients harboring an IDH mutation over those with wild-type IDH, but to date specific treatments based on this finding have not been established [19]. Targeting this mutation or its molecular or metabolic effects may be feasible. With few exceptions, the molecular findings have not impacted treatment decisions to date. However, all of these findings serve as clues that a molecular diagnosis is trending towards significantly influencing the clinical management of patients.

**Antiangiogenic therapy**

Angiogenesis is a pathologic hallmark of glioblastoma, with the expression of vascular endothelial growth factor (VEGF) among other pro-angiogenic cytokines as one of the most important regulators of angiogenesis [20]. VEGF is an essential regulator of angiogenesis, which has rendered it an appealing target in cancer therapeutics [21]. The expression of VEGF and other proangiogenic cytokines in glioblastoma results in the development of abnormal tumor vasculature characterized by tortuous, hyperpermeable vessels, increased vessel diameter, and abnormally thickened basement membranes. This aberrant tumor vasculature is believed to enhance tumor hypoxia and impair the delivery of cytotoxic chemotherapy.

Several studies have demonstrated that VEGF and its receptors can be antagonized by monoclonal antibodies to VEGF and small-molecule inhibitors of VEGF receptor 2 (VEGFR-2) [22–24]. Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling. Bevacizumab was Food and Drug Administration (FDA) approved in May 2009 for use as a single agent in patients with glioblastoma with progressive disease, following front-line therapy consisting of surgical resection, radiotherapy, and temozolomide. The incorporation of antiangiogenic therapy in the treatment of glioblastoma initially generated excitement that tumor growth could be substantially inhibited, resulting in improved patient outcomes.

In the early, uncontrolled clinical studies, impressive radiographic responses and prolongation of progression free survival were noted. Promising results were seen in single arm phase II clinical trials using the oral pan-VEGFR-2 tyrosine kinase inhibitor cediranib (AZD2171, AstraZeneca) and the anti-VEGF-A antibody bevacizumab (Avastin, Genentech/Roche). In patients with recurrent glioblastoma, a randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAIL [Recentin in Glioblastoma Alone and With Lomustine]) was performed to determine the efficacy of cediranib either as monotherapy or in combination with lomustine versus lomustine alone. The primary endpoint of prolonging progression free survival was not reached.

<table>
<thead>
<tr>
<th>Molecular Targets in Glioblastoma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cell Surface Growth Factor Receptors</strong></td>
</tr>
<tr>
<td>Epidermal growth factor receptor (EGFR)</td>
</tr>
<tr>
<td>Platelet derived growth factor receptor (PDGFR)</td>
</tr>
<tr>
<td>Vascular endothelial growth factor (VEGF)</td>
</tr>
<tr>
<td>Transforming growth factor receptor (TGFRI)</td>
</tr>
<tr>
<td>Fibroblast growth factor receptor (FGFR)</td>
</tr>
<tr>
<td><strong>Receptor Tyrosine Kinase Signaling and Downstream Effectors</strong></td>
</tr>
<tr>
<td>Ras/Mitogen-activated Protein Kinase (MAPK)</td>
</tr>
<tr>
<td>PI3-Kinase/Akt</td>
</tr>
<tr>
<td>Mammalian target of rapamycin (mTOR)</td>
</tr>
<tr>
<td>Protein kinase C</td>
</tr>
<tr>
<td>TP53</td>
</tr>
<tr>
<td>Rb (retinoblastoma) signaling</td>
</tr>
<tr>
<td><strong>Angiogenesis Inhibition</strong></td>
</tr>
<tr>
<td>Vascular endothelial growth factor receptor (VEGFR)</td>
</tr>
<tr>
<td>VEGF</td>
</tr>
<tr>
<td><strong>Other Targets</strong></td>
</tr>
<tr>
<td>Histone deacetylase (HDAC)</td>
</tr>
<tr>
<td>IDH1/2 mutations</td>
</tr>
</tbody>
</table>
and there was no demonstration that cediranib conferred a benefit, either as monotherapy or in combination with lomustine, compared to lomustine alone [25].

Bevacizumab was subsequently evaluated in phase III clinical trials for newly diagnosed glioblastoma, with unfortunately no effect on overall patient survival. Two recent large randomized phase III trials, AVAglio and RTOG 0825, demonstrated that the addition of bevacizumab to upfront treatment with radiation and temozolomide conferred no benefit in terms of overall survival in newly diagnosed glioblastoma patients when compared to the standard treatment arm [26,27]. Progression free survival was found to be prolonged in both studies by approximately 3–4 months, reaching statistical significance in the AVAglio study but not in the RTOG 0825 study based on pre-defined criteria [26,27]. Both trials additionally evaluated patient-reported outcomes including quality of life and neurocognitive testing as secondary endpoints, with divergent results as commented on by a recent editorial [28]. The AVAglio trial found improvement in or prolonged maintenance of quality of life and performance status while RTOG 0825 found a worsened quality of life and a decline in cognitive function over time. These findings have spurred conversation regarding the quality of life endpoints for each study and the role a measure such as quality of life could play in the approval of a new therapy for cancer, regardless of its effect on survival [28].

The sobering realization that VEGF pathway inhibitors result in only transitory clinical and radiographic benefit for a few months, prior to the inevitable resumption of disease progression, has prompted the effort to better understand the mechanistic basis underlying resistance to antiangiogenic therapy. The rapid and robust radiographic response of angiogenesis inhibitors suggests that they have little intrinsic antitumor activity, and that the main benefit is derived from the indirect effects secondary to reduction in cerebral edema and the potential to enhance the efficacy of other therapies. Figure 2 highlights the postcontrast radiographic response and the interval fluid attenuated inversion recovery (FLAIR) signal changes seen in the setting of the use of single agent bevacizumab in a patient with recurrent glioblastoma.

The lack of a durable response seen with the use of antiangiogenic agents has been disappointing. There is a growing body of research investigating the mechanisms underlying the resistance to anti-VEGF therapy, in an attempt to improve our current therapeutic approaches. Adaptive (evasive) resistance and intrinsic (pre-existing) non-responsiveness have emerged as the modes of resistance to antiangiogenic therapy, with multiple mechanisms believed to underlie each type [29]. Adaptive mechanisms described have included activation and/or upregulation of alternative pro-angiogenic signaling pathways within the tumor, recruitment of bone marrow derived pro-angiogenic cells, increased pericyte coverage of the tumor vasculature, and activation and enhancement of invasion and metastasis [29]. In contrast to mechanisms of adaptive resistance, it has been speculated that some glioblastoma-associated blood vessels are intrinsically resistant to antiangiogenic therapy, based on the observation of patients on clinical trials with VEGF pathway inhibitors who had no discernible reduction in contrast enhancement on
magnetic resonance imaging (MRI) after treatment with antiangiogenic therapy. A subset of patients in clinical trials for bevacizumab, sorafenib, and sunitinib was identified who did not demonstrate any transitory radiographic response or clinical benefit [30]. This lack of response was characterized by no evidence of reduction in vascular permeability, no cessation of tumor growth or retardation of growth rate, no observed quality of life benefit, and no evidence of increased survival [29]. It is speculated that these tumors likely express high levels of multiple pro-angiogenic growth factors, such as placental growth factor, in addition to VEGF or that the tumor angiogenesis is completely VEGF-independent.

**Immunotherapy**

Immune system modulation has evolved as a promising treatment modality in many malignancies, including gliomas. Immunotherapy has long been an appealing therapeutic strategy and is based on the premise of harnessing the patient’s own immune system to stimulate an antitumor response. Immunosuppression is inherently associated with glioblastoma and is mediated by a variety of mechanisms. There are a number of immunotherapy approaches being studied including the use of autologous stimulated lymphocytes, immunotherapy with cytokines and dendritic cells, and tumor or peptide based vaccines. Recent clinical trials of single peptide-based vaccine, rindopepimut (PEP-3-KLH/CDX-110), targets the 13 amino acid sequence EGFRvIII receptor antigen in EGFRvIII expressing tumors. Rindopepimut has been evaluated in two phase II clinical trials in patients with newly diagnosed glioblastoma. Following completion of concurrent chemoradiation, patients were enrolled to receive maintenance temozolomide with a rindopepimut vaccination. The results of these two trials have been encouraging with a median progression free survival of 14.2 months and 15.2 months and a median overall survival of 23.6 and 26 months suggesting that tumor-mediated immune suppression can be overcome [31,32].

In metastatic melanoma, ipilimumab, a human immunoglobulin (Ig)G1 monoclonal antibody to cytotoxic T-lymphocyte antigen 4 (CTLA-4), has been demonstrated to result in a durable response and improved overall survival when compared to non-ipilimumab containing treatment arms in randomized trials [33,34]. There have also been recent data demonstrating the effectiveness of ipilimumab in the treatment of melanoma patients with brain metastases [35,36], as evidenced by the measurable tumor reduction seen with ipilimumab used as monotherapy. Nivolumab, a fully humanized IgG4 monoclonal antibody to the immune checkpoint molecule programmed death-1 (PD-1), has also been found to have activity in metastatic melanoma as a single agent. PD-1 is a complementary checkpoint protein to CTLA-4, and Nivolumab has been shown to block PD-1, reversing the immunosuppression mediated by this molecule.

At the present time, there are no data available for ipilimumab or nivolumab in patients with malignant gliomas, but the responses seen in melanoma have generated increasing interest that the incorporation of these agents into the treatment paradigms for glioma may translate to improving patient outcomes. This hypothesis is supported by preclinical data in work done in orthotopic murine models of glioblastoma [37,38]. In these studies, ipilimumab was found to be efficacious in the central nervous system (CNS) murine models of glioma resulting in >80% of the treated animals being cured. This efficacy was associated with enhancement of CD8+ (cytotoxic) T cells without decreasing the CD4 population, suggesting successful inhibition of the immunosuppressive activity of regulatory T cells. Similar results have been demonstrated using a murine anti-PD-1 in combination with radiosurgery [39]. These results suggest that there is a therapeutic synergy in generating a robust immune response at the time of radiation-induced tumor cytotoxicity.

**Recurrent disease**

Unfortunately, despite initial multimodality treatment, all patients will experience recurrent disease warranting a change in therapy. The increasing understanding of the molecular changes of glioblastoma over time presents a major challenge in the development of effective treatments in the recurrent setting. The molecular profile of the tumor tissue obtained at time of diagnosis becomes less representative over time, as the tumor continues to accumulate mutations and develops resistance to treatment. There is a present lack of effective salvage therapies for recurrent glioblastoma. Nitrosoureas continue to be used commonly as salvage therapy and have been found not to be inferior to targeted therapies, underscoring their enduring relevance. In a phase III study comparing the targeted therapeutic agent enzastaurin, an oral serine threonine kinase inhibitor, to the nitrosourea, lomustine, enzastaurin was found not to be superior to lomustine suggesting that nitrosoureas still play an important role in the treatment of glioblastoma in the recurrent setting [40].

The determination of response to therapy is based on clinical manifestations and the interpretation of the MRI findings. Interpretation of the MRI becomes even more paramount, particularly in the absence of any clinical
deterioration in the patient. A phenomenon termed pseudoprogression has evolved to describe radiographic changes that can mimic tumor progression but actually represents radiation induced changes. Pseudoprogression is a clinically significant entity which can affect patient management and the conduct of clinical trials. This phenomenon can most commonly be appreciated in the first few months following completion of concurrent chemoradiation, and is often manifested as a transient increase in contrast enhancement following completion of radiotherapy [41]. Radiographic changes suggestive of progression particularly within the first few months after completion of concurrent chemoradiation should be interpreted with caution and followed closely before a change in therapy is made.

Conclusion
Glioblastoma is one of the most lethal human cancers. Our current standard multimodality treatment of surgery, radiation, and cytotoxic chemotherapy results in only a modest survival benefit at best for a subset of patients with glioblastoma. Radiation therapy in glioblastoma has historically been administered as fractionated, conformal external beam photon radiation, but randomized clinical trials are currently underway evaluating proton beam radiation compared to photon radiation in glioblastoma. Genomic analyses are now furthering our understanding of this molecularly heterogeneous disorder and providing insight into potential actionable targets in the development of targeted therapeutics. Antiangiogenic therapies once held great promise in the treatment of glioblastoma and, although the results have been largely disappointing, there likely is a role for angiogenesis inhibitors in the treatment of glioblastoma. The identification of this role will be contingent upon broadening our understanding of the mechanisms of mediating resistance, to help determine how to optimally incorporate the use of antiangiogenic agents in our treatment paradigm. Immunotherapy has recently been generating increasing excitement in the treatment of glioma, with clinical trials underway and, although the results have been largely disappointing, VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; FGFR, fibroblast growth factor receptor; IDH, isocitrate dehydrogenase; Ig, immunoglobulin; MGMT, O-6-methylguanine-DNA methyltransferase; MRI, magnetic resonance imaging; PI3K, phosphatidylinositol 3-kinase; PD-1, programmed death-1; Ph chromosome, Philadelphia chromosome; RTK, receptor tyrosine kinase; TACC, transforming acidic coiled-coil; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

Disclosures
Mark R. Gilbert serves on the Advisory Boards for Genentech/Roche, Abbvie, Merck and Bristol-Myers Squibb; provides research support for Genentech/Roche, Merck and GlaxoSmithKline; and receives honoraria from Genentech/Roche, Abbvie and Merck.

References


Abbreviations
AKT, protein kinase B; CML, chronic myeloid leukemia; CTLA-4, cytotoxic T-lymphocyte antigen 4; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; IDH, isocitrate dehydrogenase; Ig, immunoglobulin; MGMT, O-6-methylguanine-DNA methyltransferase; MRI, magnetic resonance imaging; PI3K, phosphatidylinositol 3-kinase; PD-1, programmed death-1; Ph chromosome, Philadelphia chromosome; RTK, receptor tyrosine kinase; TACC, transforming acidic coiled-coil; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.


